Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 27OTHER 13NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 6Sarcoma 1Genitourinary 1

Conditions

Sarcoma 108Central Nervous System Neoplasms 42Osteosarcoma 38Gliosarcoma 34Glioblastoma 34Rhabdomyosarcoma 27Lymphoma 22Fibrosarcoma 22Liposarcoma 21Leiomyosarcoma 20Neuroblastoma 19Hemangiosarcoma 19Astrocytoma 19Sarcoma, Synovial 18Neuroectodermal Tumors, Primitive, Peripheral 18Dendritic Cell Sarcoma, Interdigitating 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Neurofibrosarcoma 17Histiocytoma, Malignant Fibrous 17Brain Neoplasms 17Sarcoma, Kaposi 16Malignant mesenchymal tumor 16Burkitt Lymphoma 16Ovarian Neoplasms 15Recurrence 14Leukemia 14Sarcoma, Alveolar Soft Part 12Oligodendroglioma 12AIDS-related Kaposi sarcoma 12Hemangiopericytoma, Malignant 11

Interventions

fludarabine 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Triple Negative Breast Neoplasms × Sarcoma × Clear all
NCT07297667 2026-05-12

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Canadian Cancer Trials Group

Phase 1 Not yet recruiting
30 enrolled
BreastGenitourinarySarcoma

Carcinoma, Renal Cell, Sarcoma, Alveolar Soft Part, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡